Company: HROW
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001641172-25-009263
Chunk: 43

Company: HARROW, INC.
Filing Date: 2025-05-08
Form: 10-Q
Item: Item 1
Chunk 43
---
    March 31,  

    2025  
    2024  
    Variance 
  
    IHEEZO 
    $5,222,000  
    $2,321,000  
    $2,901,000 
  
    VEVYE 
     21,516,000  
     2,597,000  
     18,919,000 
  
    Other branded products 
     956,000  
     8,872,000  
     (7,916,000)
  
    Other revenues 
     86,000  
     79,000  
     7,000 
  
    Branded revenue, net 
     27,780,000  
     13,869,000  
     13,911,000 
  
    ImprimisRx revenue, net 
     20,051,000  
     20,718,000  
     (667,000)
  
    Total revenues, net 
    $47,831,000  
    $34,587,000  
    $13,244,000 

Other than IHEEZO and VEVYE, no other products
accounted for more than 10% of total revenues for the periods presented.

Customer and Supplier Concentrations

Substantially all of the Company’s Branded
sales are made to third-party distributors who sell the products to pharmacies and to the end-users. There were two customers who comprised
more than 10% of the Company’s Branded revenues for the three months ended March 31, 2025 and one customer who comprised more than
10% of the Company’s Branded revenues for the three months ended March 31, 2024. There were no customers who comprised more than
10% of ImprimisRx revenues for the three months ended March 31, 2025 and 2024. As of March 31, 2025 and December 31, 2024, accounts receivable
from two customers accounted for 90% and 94%, respectively, of total consolidated accounts receivable.

The Company received its active pharmaceutical
ingredients from three main suppliers during the three months ended March 31, 2025 and 2024, respectively. These suppliers collectively
accounted for 67% and 85% of active pharmaceutical ingredient purchases during the three months ended March 31,